Detected ·
Oyster Therapeutics
$60MSeries A
Oyster Therapeutics announced a $60 million Series A financing to advance its brain-penetrant tau degrader into clinical development, led by 4BIO Capital with participation from Eli Lilly, Crescent Enterprises, Actium Group, TOHO Ventures, Syncona, Oxford Science Enterprises, Mission BioCapital, and Mass General Brigham Ventures.
- Website
- —
- linkedin.com/company/98348645
- Amount
- $60 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-11 00:06:55 UTC
- Signal ID
- 82de5eea-9e42-4ec4-8c82-266d22d1937c
As the API returns it
{
"id": "82de5eea-9e42-4ec4-8c82-266d22d1937c",
"created_at": "2026-11-11T00:06:55.806799Z",
"company_name": "Oyster Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/98348645",
"event_type": "funding",
"funding_amount": 60000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Oyster Therapeutics announced a $60 million Series A financing to advance its brain-penetrant tau degrader into clinical development, led by 4BIO Capital with participation from Eli Lilly, Crescent Enterprises, Actium Group, TOHO Ventures, Syncona, Oxford Science Enterprises, Mission BioCapital, and Mass General Brigham Ventures.*"
}